Key Points
- Insider selling: Jacquelyn Sumer sold 3,742 shares at an average $13.62 on Feb. 20 (~$51k), trimming her stake 2.76%, and several other insiders (including the CEO and CFO) sold the same day for a combined ~20,466 shares (~$284k), introducing short‑term selling pressure.
- Analyst optimism and upside: Eight analysts rate the stock Buy (one Hold, one Sell) with an average price target of $29.33 and recent raises from firms like Citigroup ($33), Wedbush ($34) and Morgan Stanley ($30), implying substantial upside from the current ~$14 level.
- Pipeline and balance sheet strength: Cullinan has a market cap of roughly $827M, is trading above its 50‑ and 200‑day moving averages, and reportedly has cash north of $430M while lead asset CLN‑049 shows ~30% complete remission in AML, supporting its clinical upside and potential accelerated approval path.
Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jacquelyn Sumer sold 3,742 shares of the firm's stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $13.62, for a total value of $50,966.04. Following the completion of the transaction, the insider owned 131,690 shares of the company's stock, valued at approximately $1,793,617.80. The trade was a 2.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Cullinan Therapeutics Stock Up 2.5%
NASDAQ CGEM opened at $13.99 on Tuesday. The firm has a market capitalization of $826.53 million, a PE ratio of -4.23 and a beta of -0.09. The stock's 50 day moving average is $11.33 and its 200 day moving average is $9.22. Cullinan Therapeutics, Inc. has a twelve month low of $5.68 and a twelve month high of $14.51.
Analysts Set New Price Targets
A number of brokerages recently issued reports on CGEM. Morgan Stanley reissued an "overweight" rating and set a $30.00 price target on shares of Cullinan Therapeutics in a research report on Thursday, January 8th. Citigroup assumed coverage on shares of Cullinan Therapeutics in a research note on Tuesday, February 17th. They set a "buy" rating and a $33.00 target price for the company. HC Wainwright boosted their price target on Cullinan Therapeutics from $26.00 to $27.00 and gave the stock a "buy" rating in a research report on Thursday, January 8th. Wedbush upped their price target on Cullinan Therapeutics from $25.00 to $34.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 9th. Finally, Zacks Research cut Cullinan Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 19th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Cullinan Therapeutics has an average rating of "Moderate Buy" and an average price target of $29.33.
Check Out Our Latest Research Report on CGEM
Institutional Trading of Cullinan Therapeutics
Large investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd increased its position in shares of Cullinan Therapeutics by 62.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,696 shares of the company's stock valued at $28,000 after acquiring an additional 1,036 shares during the period. CWM LLC grew its stake in Cullinan Therapeutics by 51.5% during the 4th quarter. CWM LLC now owns 3,876 shares of the company's stock valued at $40,000 after purchasing an additional 1,318 shares during the last quarter. Signaturefd LLC increased its holdings in shares of Cullinan Therapeutics by 689.7% in the fourth quarter. Signaturefd LLC now owns 4,130 shares of the company's stock valued at $43,000 after purchasing an additional 3,607 shares during the period. SG Americas Securities LLC purchased a new position in shares of Cullinan Therapeutics in the third quarter worth about $62,000. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Cullinan Therapeutics by 44.6% during the second quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company's stock worth $62,000 after purchasing an additional 2,523 shares during the period. Hedge funds and other institutional investors own 86.31% of the company's stock.
Key Stories Impacting Cullinan Therapeutics
Here are the key news stories impacting Cullinan Therapeutics this week:
- Positive Sentiment: Analyst bullish thesis — A recent write-up upgrades Cullinan to a Buy, citing a deep T‑cell engager pipeline, strong management, long-lived IP and a cash position north of $430M that supports development. The note highlights CLN‑049 (FLT3xCD3) showing ~30% complete remission rates in AML, favorable safety, broad applicability and a plausible single‑arm accelerated approval path, all of which underpin upside expectations. Seeking Alpha: Thesis Strengthening For This T-Cell Engager Specialist
- Neutral Sentiment: Technical/fundamental context — The stock is trading above its 50‑day ($11.26) and 200‑day ($9.17) moving averages and remains well off its 52‑week low, reflecting recent positive momentum; market cap is roughly $827M. MarketBeat: CGEM profile
- Negative Sentiment: Insider sales — CEO Nadim Ahmed sold 16,381 shares (≈$223k) on Feb 20, trimming his stake ~3.9%. CEO Filing
- Negative Sentiment: Insider sales — CFO Mary Kay Fenton sold 4,398 shares (≈$59.9k) on Feb 20, reducing her position ~3.4%. CFO Filing
- Negative Sentiment: Insider sales — Other insiders (Jennifer Michaelson, Jacquelyn Sumer, Jeffrey A. Jones) sold on Feb 20 (combined ~20,466 shares, ≈$284k total), each trimming low-single‑digit percentages of their holdings. The simultaneity and size of these sales introduce short‑term selling pressure despite the bullish clinical narrative. Insider Filings (examples)
About Cullinan Therapeutics
(
Get Free Report)
Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
